Welcome visitor Log In - or - Register
(
0 items /
$0.00
)
View Cart
Check Out
four ways
Quick Search:
BGB-283 (Lifirafenib)
BGB-283 (Lifirafenib) is an orally available dual RAF kinase/EGFR inhibitor. It potently inhibits BRAF family proteins (wild-type ARAF, BRAF, CRAF and BRAF V600E), BRAF(V600E)-activated ERK phosphorylation and cell proliferation, and demonstrates selective cytotoxicity and preferentially inhibits proliferation of cancer cells harboring BRAF(V600E) and EGFR mutation/amplification. Further, it uniquely displays inhibitory activity towards both BRAF monomeric and dimeric forms, and is considered to be the next generation inhibitor to potentially address resistances associated with increased BRAF dimer formation in response to treatment with first-generation BRAF inhibitors.
Catalog NO: CT-BGB283
Synonym: Lifirafenib, BGB283
CAS NO: 1446090-77-2
Mol. Formula: C25H17F3N4O3∙1.3H2O
MW: 501.8
** in vivo grade material, >99.5% by achiral and chiral HPLCs. A milk-white powder (pic attached), single isomer (out of possible four), hydrate, validated by quantitative microanalysis. Bulk stock!!. Same day shipping.